Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Kobayashi Pharmaceuticals
Pharmaceutical Preparation ManufacturingJapanPNK: KBYPF
Last verified 2 months agokobayashi.co.jp
Kobayashi Pharmaceuticals, a prominent player in the pharmaceutical preparation manufacturing industry, is headquartered in Japan (JP) and operates extensively across Asia and beyond. Founded in 1900, the company has established a strong reputation for its innovative healthcare solutions, focusing on over-the-counter medications, dietary supplements, and personal care products.
With a commitment to quality and efficacy, Kobayashi Pharmaceuticals offers unique formulations that cater to diverse consumer needs. The company has achieved significant milestones, including numerous patents and awards for its product development. Renowned for its market position, Kobayashi continues to lead in various therapeutic areas, making it a trusted name in the pharmaceutical sector.
51
DitchCarbon score
+9 vs industry average
Kobayashi Pharmaceuticals’s score of 51 is higher than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Kobayashi Pharmaceuticals?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
High
Pharmaceutical Preparation Manufacturing has above-average carbon intensity
Industry performance
0.243
02025
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Emissions trajectory 2020 – 2027
20202021202220232024202520262027
Reported emissions
Scope 1
•••kg CO₂e
Scope 2
•••kg CO₂e
Scope 3
•••kg CO₂e
Total reported
•••kg CO₂e
Scope 3 accounts for ••• of total emissions.
Kobayashi Pharmaceuticals's reported carbon emissions
Kobayashi Pharmaceuticals, a Japanese Pharmaceutical Preparation Manufacturing company, reported its 2024 Scope 1 emissions as 8,000,000 kg CO2e, Scope 2 emissions as 19,000,000 kg CO2e (market-based), and Scope 3 emissions as 488,000,000 kg CO2e. For 2023, the company reported Scope 1 emissions of 6,000,000 kg CO2e, Scope 2 emissions of 18,000,000 kg CO2e, and Scope 3 emissions of 559,000,000 kg CO2e.
Kobayashi Pharmaceuticals has set Science Based Targets initiative (SBTi) approved near-term targets. The company commits to reduce absolute Scope 1 and 2 GHG emissions by 51% by 2030, using 2018 as a base year. Additionally, it aims to reduce absolute Scope 3 GHG emissions by 15% within the same timeframe, also from a 2018 base year.
Assessing Kobayashi Pharmaceuticals as a supplier or portfolio company?
- See verified emissions data for over 2 million organizations
- View emissions forecasts for Kobayashi Pharmaceuticals and the organizations you buy from or invest in
- Get PCAF data quality (DQ) scores, including for private organizations
Kobayashi Pharmaceuticals’s Climate Goals (2030 & 2050)
3 goals2030
15% reduction in scope 3 total
KOBAYASHI Pharmaceutical Co. , Ltd. also commits to reduce absolute scope 3 GHG emissions 15% within the same timeframe
On track15%
2030
51% reduction in Scope 1
KOBAYASHI Pharmaceutical Co. , Ltd. commits to reduce absolute scope 1 and 2 GHG emissions 51% by 2030 from a 2018 base year.
Behind target51%
2030
51% reduction in Scope 2
KOBAYASHI Pharmaceutical Co. , Ltd. commits to reduce absolute scope 1 and 2 GHG emissions 51% by 2030 from a 2018 base year.
Behind target51%
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
Scope 3 top emissions categories
1 of 15 categories disclosedSee all scope 3 categories
Already have an account? Sign in now
Climate initiatives
Science Based Targets Initiative
2030 targetSee details
Active
Carbon Disclosure Project
Sign in to view
Active
The Climate Pledge
See details
Not active
UN Global Compact Climate Champions initiative
See details
Not active
RE 100
See details
Not active
Climate Action 100
See details
Not active
Emissions comparison with industry peers
View similar organisationsCompanyCountryIndustryLast updatedScoreDetails
Kobayashi Pharmaceuticals2 months ago
51
Need this data for financed emissions?
PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
Frequently asked questions
Common questions about Kobayashi Pharmaceuticals’s sustainability data and climate commitments
For 2024, Kobayashi Pharmaceuticals reported total carbon emissions of approximately 515 million kg CO2e. This includes about 8 million kg CO2e from Scope 1, roughly 19 million kg CO2e from Scope 2 (market-based), and a substantial 488 million kg CO2e from Scope 3. The vast majority of the company's carbon footprint, nearly 95%, originates from its Scope 3 emissions, highlighting the significant impact of its value chain in the Pharmaceutical Preparation Manufacturing sector.
Data year: 2024
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more